Scoffone Viola Camilla, Trespidi Gabriele, Barbieri Giulia, Arshad Arooba, Israyilova Aygun, Buroni Silvia
Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy.
Laboratory of Microbiology, Center of Excellence, Baku State University, AZ1148 Baku, Azerbaijan.
Antibiotics (Basel). 2025 Jan 14;14(1):85. doi: 10.3390/antibiotics14010085.
is considered one of the prioritized ESKAPE microorganisms for the research and development of novel treatments by the World Health Organization, especially because of its remarkable persistence and drug resistance. In this review, we describe how this can be acquired by the enzymatic degradation of antibiotics, target site modification, altered membrane permeability, multidrug efflux pumps, and their ability to form biofilms. Also, the evolution of drug resistance in , which is mainly driven by mobile genetic elements, is reported, with particular reference to plasmid-associated resistance, resistance islands, and insertion sequences. Finally, an overview of existing, new, and alternative therapies is provided.
被世界卫生组织视为新型治疗方法研发中优先考虑的ESKAPE微生物之一,特别是由于其显著的持久性和耐药性。在本综述中,我们描述了它如何通过抗生素的酶促降解、靶位点修饰、膜通透性改变、多药外排泵以及形成生物膜的能力来获得耐药性。此外,还报道了主要由移动遗传元件驱动的[具体微生物名称]耐药性的演变,特别提及了质粒相关耐药性、耐药岛和插入序列。最后,提供了现有、新的和替代疗法的概述。 (注:原文中“ In this review, we describe how this can be acquired by...”一句中的“this”指代不明,推测是某种微生物,但未明确写出,翻译时保留原文指代不明的情况。)